| Schedule of Segment Net Loss, Including Disaggregated Components of Operating Expenses |
The Company's consolidated and segment net loss, including disaggregated components of operating expenses is as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
|
|
|
|
|
|
2026 |
|
|
2025 |
|
Collaboration revenue |
|
|
|
|
|
|
|
$ |
1,034 |
|
|
$ |
566 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development: |
|
|
|
|
|
|
|
|
|
|
|
|
Verekitug program: |
|
|
|
|
|
|
|
|
|
|
|
|
COPD indication |
|
|
|
|
|
|
|
|
10,962 |
|
|
|
5,687 |
|
Asthma indication |
|
|
|
|
|
|
|
|
10,710 |
|
|
|
10,021 |
|
CRSwNP indication |
|
|
|
|
|
|
|
|
1,089 |
|
|
|
2,763 |
|
Personnel expenses |
|
|
|
|
|
|
|
|
7,201 |
|
|
|
3,705 |
|
Manufacturing costs |
|
|
|
|
|
|
|
|
4,973 |
|
|
|
2,129 |
|
Professional fees and other |
|
|
|
|
|
|
|
|
1,630 |
|
|
|
1,492 |
|
Total research and development expenses |
|
|
|
|
|
|
|
|
36,565 |
|
|
|
25,797 |
|
General and administrative: |
|
|
|
|
|
|
|
|
|
|
|
|
Personnel expenses |
|
|
|
|
|
|
|
|
4,937 |
|
|
|
4,232 |
|
Professional fees |
|
|
|
|
|
|
|
|
2,034 |
|
|
|
1,496 |
|
Other |
|
|
|
|
|
|
|
|
1,113 |
|
|
|
1,054 |
|
Total general and administrative expenses |
|
|
|
|
|
|
|
|
8,084 |
|
|
|
6,782 |
|
Total operating expenses |
|
|
|
|
|
|
|
|
44,649 |
|
|
|
32,579 |
|
Loss from operations |
|
|
|
|
|
|
|
|
(43,615 |
) |
|
|
(32,013 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
|
|
|
|
|
|
3,054 |
|
|
|
4,743 |
|
Other expense, net |
|
|
|
|
|
|
|
|
(30 |
) |
|
|
— |
|
Total other income, net |
|
|
|
|
|
|
|
|
3,024 |
|
|
|
4,743 |
|
Segment and consolidated net loss |
|
|
|
|
|
|
|
$ |
(40,591 |
) |
|
$ |
(27,270 |
) |
|